Sparx has returned to lead the OUVC-backed cell-based therapeutic technology developer’s series B round, which brought its overall funding to almost $45m.

ThinkCyte, a Japan-based cellular treatment developer backed by Osaka University, raised ¥2.85bn ($26m) in a series B round yesterday led by asset manager Sparx’s Mirai Creation Fund 2.
Trading group Itochu’s corporate venturing arm Itochu Technology Ventures, healthcare provider Sysmex Corporation and financial services firms SBI Group and Sumitomo Mitsui Trust’s Japan Co-Invest vehicle took part in the round, which lifted the company’s total funding to nearly $45m.
Founded in 2016, ThinkCyte is developing advanced imaging, artificial intelligence…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in